Neuroimaging Predictors of Treatment Failure in Adult New-onset Epilepsy
|ClinicalTrials.gov Identifier: NCT01320670|
Recruitment Status : Unknown
Verified January 2013 by Bernd Pohlmann-Eden, Capital District Health Authority, Canada.
Recruitment status was: Recruiting
First Posted : March 22, 2011
Last Update Posted : January 21, 2013
Epilepsy, defined as recurrent, unprovoked seizures, is a common condition, affecting 0.5-1% of the general population. People with uncontrolled epilepsy suffer poor health and increased mortality due to their condition. They frequently experience social stigma and are socioeconomically disadvantaged. It is therefore imperative to help them gain control of their seizures as quickly as possible. A wide range of antiepileptic drugs (AEDs) has become available to treat people with epilepsy. However, despite maximal therapy, approximately 20-40% show pharmacoresistance (PR) and thus continue to have seizures.
We do not understand why a significant proportion of people with epilepsy have PR. For any given patient presenting with a first unprovoked seizure, we are unable to predict PR at the time of presentation. At least 2 different AEDs must be tried at maximum doses for a year before we can diagnose PR. At this point, surgical therapies become an increasingly urgent consideration.
Retrospective magnetic resonance imaging (MRI) studies in the chronic stages of epilepsy have shown that patients with PR are more likely to have focal structural lesions in the brain, and in particular to have signs of damage to the hippocampi. For example, there are retrospective data suggesting that a decreased hippocampal N-acetylaspartate (NAA)/creatine ratio (measured by magnetic resonance spectroscopy [MRS]) and hippocampal atrophy (determined by hippocampal volumetry) correlate with PR. However, it is not clear whether these findings reflect the underlying pathophysiology of PR, or simply reflect the effects of chronic seizures and chronic drug treatment on the brain.
The First Seizure Clinic at the Halifax Infirmary represents a unique opportunity for prospective, longitudinal studies of patients who present with a first seizure or with newly diagnosed epilepsy. In these patients, advanced neuroimaging techniques at presentation might show changes that truly reflect the underlying pathophysiology of PR, rather than changes that develop as a consequence of prolonged seizures and drug treatment. Neuroimaging follow-up might help us to understand the pathophysiologic changes that accompany the evolution of PR. Ultimately, it is our hope to combine neuroimaging features and clinical features of patients with PR in a predictive model that would help us to predict PR at presentation.
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||50 participants|
|Official Title:||Neuroimaging Predictors of Treatment Failure in Adult New-onset Epilepsy|
|Study Start Date :||June 2011|
|Estimated Primary Completion Date :||June 2014|
|Estimated Study Completion Date :||December 2014|
- Pharmacoresistance [ Time Frame: 12 months ]At the end of the study, each participant will be categorized as "PR" or "not PR" by the principal investigator. Participants will be categorized as PR if they have not achieved seizure freedom within 1 year of therapy, using at least 2 AEDs at maximal dose.
- Hippocampal NAA/creatine ratio [ Time Frame: 12 months ]Hippocampal NAA/creatine ratio will be determined by single voxel magnetic resonance spectroscopy.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01320670
|Contact: Bernhard Pohlmann-Eden, MD, PhDemail@example.com|
|Contact: Matthias H Schmidt, MDfirstname.lastname@example.org|
|Canada, Nova Scotia|
|Halifax, Nova Scotia, Canada, B3H 3A7|
|Contact: Bernhard Pohlmann-Eden, MD, PhD 902-473-1882 email@example.com|
|Contact: Matthias H Schmidt, MD 902-473-5332 firstname.lastname@example.org|
|Principal Investigator: Bernhard Pohlmann-Eden, MD, PhD|
|Sub-Investigator: Matthias H Schmidt, MD|
|Principal Investigator:||Bernd Pohlmann-Eden, MD, PhD||Capital Health, Canada|